|
1
|
Tejeda-Maldonado J, García-Juárez I,
Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M,
Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF and
Carrillo-Pérez DL: Diagnosis and treatment of hepatocellular
carcinoma: An update. World J Hepatol. 7:362–376. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lencioni R, Petruzzi P and Crocetti L:
Chemoembolization of hepatocellular carcinoma. Semin Intervent
Radiol. 30:3–11. 2013. View Article : Google Scholar :
|
|
3
|
Kim HY and Park JW: Clinical trials of
combined molecular targeted therapy and locoregional therapy in
hepatocellular carcinoma: Past, present, and future. Liver Cancer.
3:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen C and Wang G: Mechanisms of
hepatocellular carcinoma and challenges and opportunities for
molecular targeted therapy. World J Hepatol. 7:1964–1970. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaitheesvaran B, Xu J, Yee J, Q-Y L, Go
VL, Xiao GG and Lee WN: The Warburg effect: A balance of flux
analysis. Metabolomics. 11:787–796. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jang M, Kim SS and Lee J: Cancer cell
metabolism: Implications for therapeutic targets. Exp Mol Med.
45:e452013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Granja S, Pinheiro C, Reis RM, Martinho O
and Baltazar F: Glucose addiction in cancer therapy: Advances and
drawbacks. Curr Drug Metab. 16:221–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ngo DC, Ververis K, Tortorella SM and
Karagiannis TC: Introduction to the molecular basis of cancer
metabolism and the Warburg effect. Mol Biol rep. 42:819–823. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shoshan MC: 3-Bromopyruvate: Targets and
outcomes. J Bioenerg Biomembr. 44:7–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ganapathy-Kanniappan S, Geschwind JF,
Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed
LH, Rao PP, Ota S, et al: Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell
death. Anticancer Res. 29:4909–4918. 2009.
|
|
11
|
Cardaci S, Desideri E and Ciriolo MR:
Targeting aerobic glycolysis: 3-bromopyruvate as a promising
anticancer drug. J Bioenerg Biomembr. 44:17–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davies B and Fried M: The L19 ribosomal
protein gene (RPL19): Gene organization, chromosomal mapping, and
novel promoter region. Genomics. 25:372–380. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Casimiro MC, Velasco-Velázquez M,
Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function
in cancer and the CDK inhibitor landscape: Past and present. Expert
Opin Investig Drugs. 23:295–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vandooren J, Van den Steen PE and
Opdenakker G: Biochemistry and molecular biology of gelatinase B or
matrix metallopro-teinase-9 (MMP-9): The next decade. Crit Rev
Biochem Mol Biol. 48:222–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ganapathy-Kanniappan S, Geschwind JF,
Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy
R and Vali M: 3-Bromopyruvate induces endoplasmic reticulum stress,
overcomes autophagy and causes apoptosis in human HCC cell lines.
Anticancer Res. 30:923–935. 2010.PubMed/NCBI
|
|
16
|
Ganapathy-Kanniappan S, Kunjithapatham R,
Torbenson MS, Rao PP, Carson KA, Buijs M, Vali M and Geschwind JF:
Human hepatocellular carcinoma in a mouse model: Assessment of
tumor response to percutaneous ablation by using
glyceral-dehyde-3-phosphate dehydrogenase antagonists. Radiology.
262:834–845. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu XH, Zheng XF and Wang YL: Inhibitive
effect of 3-bromo-pyruvic acid on human breast cancer MCF-7 cells
involves cell cycle arrest and apoptotic induction. Chin Med J
(Engl). 122:1681–1685. 2009.
|
|
18
|
Feng X, Wang P, Liu Q, Zhang T, Mai B and
Wang X: Glycolytic inhibitors 2-deoxyglucose and 3-bromopyruvate
synergize with photodynamic therapy respectively to inhibit cell
migration. J Bioenerg Biomembr. 47:189–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jae HJ, Chung JW, Park HS, Lee MJ, Lee KC,
Kim HC, Yoon JH, Chung H and Park JH: The antitumor effect and
hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: In
vivo investigation of intraarterial administration in a rabbit VX2
hepatoma model. Korean J Radiol. 10:596–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu SJ, Yoon JH, Yang JI, Cho EJ, Kwak MS,
Jang ES, Lee JH, Kim YJ, Lee HS and Kim CY: Enhancement of
hexokinase II inhibitor-induced apoptosis in hepatocellular
carcinoma cells via augmenting Er stress and anti-angiogenesis by
protein disulfide isomerase inhibition. J Bioenerg Biomembr.
44:101–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liapi E and Geschwind JF: Interventional
oncology: new options for interstitial treatments and intravascular
approaches: targeting tumor metabolism via a loco-regional
approach: a new therapy against liver cancer. J Hepatobiliary
Pancreat Sci. 17:405–406. 2010. View Article : Google Scholar
|
|
22
|
Geschwind JF, Ko YH, Torbenson MS, Magee C
and Pedersen PL: Novel therapy for liver cancer: Direct
intraarterial injection of a potent inhibitor of ATP production.
Cancer Res. 62:3909–3913. 2002.PubMed/NCBI
|
